Revenue
2022
2023
2024
2025
Nuvectis Pharma, Inc. (NVCT)
Price$18.57Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | N/A |
| Research & development | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M |
| Operating expenses | $27.6M | $19.8M | $22.9M | $19.2M | N/A |
| Operating income | −$27.6M | −$19.8M | −$22.9M | −$19.2M | −$12.9M |
| EBITDA | −$27.6M | −$19.8M | −$22.9M | −$19.2M | N/A |
| Net income | −$26.4M | −$19.0M | −$22.3M | −$19.1M | −$12.9M |
| Basic EPSper basic share | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| Diluted EPSper diluted share | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BENTSUR RON | 3.69M |
Mosseri Marlio Charles | 3.3M |
Poradosu Enrique | 1.81M |
Shemesh Shay | 1.79M |
TANG CAPITAL MANAGEMENT LLC | 1.55M |
BlackRock, Inc. | 1M |
PERCEPTIVE ADVISORS LLC | 1M |
Soleus Capital Management, L.P. | 1M |
VANGUARD CAPITAL MANAGEMENT LLC | 872.48K |
IRIDIAN ASSET MANAGEMENT LLC/CT | 777.08K |
GEODE CAPITAL MANAGEMENT, LLC | 432.27K |
SPHERA FUNDS MANAGEMENT LTD. | 382.95K |
BALDWIN WEALTH PARTNERS LLC/MA | 382.02K |
Occam Crest Management LP | 357.15K |
Alyeska Investment Group, L.P. | 275K |
STATE STREET CORP | 248.2K |
Carson Michael J. | 230.12K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 217.29K |
Avidity Partners Management LP | 200K |
Kalehua Capital Management LLC | 200K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 30, 2026Form 4 | Mosseri Marlio CharlesTenPercentOwner | BuyCommon Stock · indirect | 50.0K | $18.32 | $916.0K | 3.19M |
| Jun 30, 2026Form 4 | BENTSUR RONChairman & CEO | BuyCommon Stock | 12.5K | $20.00 | $250.0K | 3.69M |
| Nov 5, 2025Form 4 | BENTSUR RONChairman & CEO | BuyCommon Stock | 5.0K | $5.72 | $28.6K | 3.53M |
| Nov 5, 2025Form 4 | Sanchez JuanDirector | BuyCommon Stock | 13.0K | $5.79 | $75.3K | 78.2K |
| Nov 5, 2025Form 4 | Kaplan Matthew L.Director | BuyCommon Stock | 11.0K | $5.84 | $64.2K | 124.8K |
Community posts
Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease ...
